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To estimate the productivity costs of premature mortality due to cancer in Australia, in aggre-
gate and for the 26 most prevalent cancer sites.
Methods
A human capital approach was adopted to estimate the long term impacts of Australian can-
cer deaths in 2003. Using population mortality data, the labour force participation and the
present value of lifetime income (PVLI) forgone due to premature mortality was estimated
based on individual characteristics at the time of death including age, sex and socioeco-
nomic status. Outcomes were modelled to the year 2030 using economic data from a
national microsimulation model. A discount rate of 3% was applied and costs were reported
in 2016 Australian dollars.
Results
Premature deaths from cancer in 2003 resulted in 88,000 working years lost and a cost of
$4.2 billion in the PVLI forgone. Costs were close to three times higher in males than
females due to the higher number of premature deaths in men, combined with higher levels
of workforce participation and income. Lung, colorectal and brain cancers accounted for the
highest proportion of costs, while testicular cancer was the most costly cancer site per
death.
Conclusions
The productivity costs of premature mortality due to cancer are significant. These results
provide an economic measure of the cancer burden which may assist decision makers in
allocating scare resources amongst competing priorities.
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Introduction
Cancer accounts for 8.2 million deaths and 196.3 million years of healthy life lost globally each
year [1]. Despite improving the survival rates, the occurrence of cancer is expected to continue
to increase due to population growth and ageing, as well as the increasing prevalence of estab-
lished but preventable risk factors including smoking, overweight and physical inactivity [2].
While the costs imposed by cancer on the health care system are well documented, there is
an increasing recognition of the impact of cancer on economic productivity. The productivity
costs associated with premature mortality as a proportion of the total costs of cancer have been
found to be significant [3, 4], and a number of recent studies have estimated the productivity
costs of cancer mortality across countries in Europe, the US and Asia [3–11]. These studies
have produced wide ranging estimates of productivity losses of between $28,569 per uterine
cancer death in Puerto Rico [12] to $1.3 million per testicular cancer death in the US [5].
A 2014 review of studies calculating premature mortality losses from cancer in 2000–2013
revealed the lack of cancer sites assessed to be a major gap in the evidence base, with most
studies focussing on a single or limited number of the most common cancer sites. There was
also a predominance of studies from Europe and the US, with limited evidence from other
countries. The review concluded that comprehensive, standardised estimates of premature
mortality losses in different settings are needed if these measures are to be useful in assessing
the societal cancer burden.
The aim of this paper is to address this gap in the evidence by estimating the productivity
costs associated with premature deaths due to cancer in Australia. We use evidence from a
microsimulation model to quantify the economic impacts across all cancers, as well as the 26
most prevalent cancer sites, using a consistent and rigorous methodology. Outcomes were
modelled to the year 2030 and are reported in terms of the working years and present value of
lifetime income (PVLI) lost due to mortality. Distributional analyses of these impacts by age
and sex are also presented.
Methods
We adopted the human capital approach to estimate the potential economic gains forgone due
to premature cancer related mortality. This approach is based on the premise that, in the event
a death of an individual could have been prevented, the individual would go on to live a typical
life, earning income and contributing to the nations productivity [13]. This is the traditional
method for valuing the productivity related costs of illness [14], and it remains the dominant
approach in the recent literature [6].
The long term costs of cancer mortality were extracted from LifeLossMOD, a previously
developed microsimulation model to estimate the economic impacts of all cause premature
mortality. The process by which LifeLossMOD was developed is described in detail in Carter
et al [15] and is summarised below. For the purpose of this study, cancer deaths were extracted
from the model based on the WHO International Classification of Diseases, 10th revision
(ICD-10) code recorded as the underlying cause of death on the official death certificate
(codes C00–97) [16]. A full list of the ICD-10 codes associated with each cancer type reported
is included in S1 Table.
Developing the model
The structure of the model is outlined in Fig 1. LifeLossMOD estimates the potential economic
gains forgone due to premature mortality by assigning a counterfactual lifespan to each indi-
vidual that died prematurely in 2003. A premature death was defined as occurring before the
age of 80 years, which was close to the Australian life expectancy [17]. The model was based
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around a population mortality dataset that contained information on the age, sex, cause of
death and socio-economic status for every individual whose death was recorded in that year
[18].
The process of assigning counterfactual lifespans to each cancer death was based on the
premise that individuals with the same demographic characteristics could be assumed to expe-
rience similar life patterns and events including hours worked, income earned and retirement
age over a period of time into the future. A counterfactual death could occur at any given age,
and was modelled based on the age, sex and socioeconomic status of an individual at the time
of their premature death in 2003. Information on these life patterns was obtained from a sepa-
rate microsimulation model, APPSIM.
APPSIM is a dynamic model of the Australian population that was developed in collabora-
tion with the Australian government with the aim of evaluating the impact of future fiscal and
social policies [19]. The model uses a one percent sample of the 2001 Australian Census
(188,000 records) as its base population. Large longitudinal survey datasets [20, 21] and official
demographic data and projections [22] were used to generate transition probabilities for
events within the model. These probabilities were then applied to the cohort of individuals
within the model to annually update the population’s characteristics up to the year 2030.
LifeLossMOD was then able to match individuals in the 2003 mortality dataset at random
with similar individuals in the 2003 APPSIM population based on each available combination
of age category, sex and the socioeconomic status. To allow for the effects of uncertainty in the
matching of records, the process was replicated 100 times to create 100 unique datasets. These
100 simulated datasets are what comprises LifeLossMOD. The results contained throughout
this paper report the mean of the 100 datasets. Where present, 95% confidence intervals have
been calculated using the percentile method.
Estimating the productivity impacts of premature mortality in 2003
The projected labour force participation forgone due to premature cancer related mortality in
2003 was estimated by accumulating the weekly hours worked by each individual in the model
over the period from 2003 to 2030. For each individual, a full time equivalent working year
Fig 1. LifeLossMOD: Structure of the model and relationships between key data items
doi:10.1371/journal.pone.0167521.g001
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was derived by dividing the accumulated number of hours worked by the number of hours in
a standard Australian working year [23].
The productivity costs of premature cancer related mortality were estimated by deriving the
Present Value of Lifetime Income (PVLI) forgone. The PVLI represents the lifetime stream of
private income an individual is expected to earn, valued in today’s currency (thereby excluding
the effects of inflation). The estimate includes earnings from wages and salaries as well as pri-
vate income generated from other sources including business profits and investments. Trans-
fer payments were excluded to avoid double-counting on a macroeconomic level. The
modelled income was estimated on an annual basis for each individual in the model, taking
into account a range of factors including the individual’s age, sex, labour force participation
and life expectancy. Total income was assumed to grow at a rate of 1% per annum above infla-
tion [24] and a discount rate of 3% was applied. The resulting incomes were inflated from
AUD 2010 to AUD 2016 using the national Consumer Price Index [25].
Results
Table 1 provides a summary of the total number of premature cancer related deaths included
in this study by age and sex, as well as the counterfactual years of life lost (YLL) between 2003
and 2030. Male deaths accounted for 58% of the total number of deaths and 56% of the total
years of life lost. Deaths occurring between the ages of 65 and 80 accounted for the majority of
deaths in both men and women.
The labour force analysis revealed that a total of 88,000 working years were lost due to prema-
ture cancer deaths occurring in 2003, with male deaths accounting for 61,000 working years and
female deaths accounting for 27,000 (Fig 2). Deaths occurring between the ages of 45 to 64 years
were responsible for over 60% of the number of working years lost for both men and women.
The PVLI lost due to cancer deaths in 2003 was estimated to be $4.20 billion (95% CI
$4.14–$4.26 billion) over the period between 2003 and 2030 (Table 2). Male deaths accounted
for 74% of the total PVLI lost, which was a function of the higher number of premature deaths
among men (Table 1), their higher labour force participation (Fig 2), and their higher average
incomes [26]. Deaths occurring between the ages of 35 and 64 accounted for 82% of the total
PVLI impact.
The PVLI lost due to premature mortality by cancer site was estimated (Table 3). Lung can-
cer, followed by colorectal cancer, were found to be responsible for the greatest loss in PVLI,
together accounting for 30% of the total PVLI impact. Testicular cancer was found to be the
most costly cancer by site with each death resulting in an average PVLI loss of $793,000. This
Table 1. Number of deaths and YLL from premature cancer-related mortality in 2003.
Age Male Female Total
Deaths in 2003 Counterfactual YLL to 2030 Deaths in 2003 Counterfactual YLL to 2030 Deaths in 2003 Counterfactual YLL to 2030
<15 54 1,261 35 804 89 2,064
15–24 57 1,345 42 980 99 2,326
25–34 121 2,791 153 3,568 274 6,359
35–44 422 9,783 524 12,396 946 22,179
45–54 1,338 31,069 1,376 32,928 2,714 63,997
55–64 3,385 73,828 2,497 56,708 5,882 130,536
65–80 9,674 141,598 6,055 100,115 15,729 241,713
Total 15,051 261,675 10,682 207,499 25,733 469,174
YLL = years of life lost
doi:10.1371/journal.pone.0167521.t001
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Fig 2. Working years forgone due to premature mortality from cancer in 2003, modelled to the year 2030. Hatched
bar, males; solid bar, females.
doi:10.1371/journal.pone.0167521.g002
Table 2. PVLI lost due to premature mortality in from cancer in 2003, by age and sex.
PVLI ($ millions) 95% CI % of total
Male
<15 14 42,675 0%
15–24 45 40–51 1%
25–34 142 126–152 3%
35–44 505 505–487 12%
45–54 1,084 1,054–1,113 26%
55–64 950 923–975 23%
65–80 388 373–407 9%
Total 3,128 3,082–3,178 74%
Female
<15 17 14–21 0%
15–24 22 18–26 1%
25–34 79 70–87 2%
35–44 233 217–246 6%
45–54 382 362–400 9%
55–64 269 256–287 6%
65–80 68 63–75 2%
Total 1,071 1,046–1,106 26%
All 4,200 4,140–4,258 100%
PVLI = Present value of lifetime income; CI = confidence interval
doi:10.1371/journal.pone.0167521.t002
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was followed by bone and connective tissue cancers ($368,000 per death) and brain cancer
($325,000 per death).
The diseases associated with the highest total PVLI loss for both men and women were
assessed across ten year age categories (Fig 3). For men aged under 45, brain cancer resulted in
the greatest loss in PVLI ($101 million). Lung cancer had the highest impact in men aged 45 to
80 ($504 million) followed by colorectal cancer ($295 million). Melanoma and lymphoma
were the fourth and fifth most costly cancers overall. In women, the PVLI lost due to breast
cancer dominated the cost of all other cancers for women aged 25 to 64 ($260 million). The
next most costly cancer sites for women in terms of the total PVLI loss were lung, colorectal,
ovary and brain.
Full individual level datasets summarising the modelled working years (S2 Table) and PVLI
forgone (S3 Table) due to premature cancer mortality by age, sex and cancer type is contained
in the Supporting Information files.
Table 3. Cumulative GDP impacts of premature mortality (2003 to 2030).








PVLI lost per death
($000’s)
Lung cancer 15,943 765 738–785 18% 5,746 133
Colorectal cancer 10,332 497 471–516 12% 3,253 153
Brain cancer 6,571 326 309–340 8% 1,003 325
Breast cancer 7,519 307 293–324 7% 2,171 142
Melanoma 4,897 249 239–265 6% 867 288
Lymphoma 4,263 209 193–221 5% 1,101 190
Leukaemia 4,180 201 190–213 5% 990 203
Pancreatic cancer 4,083 197 187–207 5% 1,398 141
Oesophageal cancer 3,134 156 145–167 4% 849 184
Stomach cancer 3,113 154 145–165 4% 830 186
Liver cancer (excluding hepatitis B and
C related)
2,929 150 139–158 4% 720 209
Mouth and oropharynx cancers 2,805 142 134–151 3% 566 250
Prostate cancer 2,605 125 115–135 3% 1,547 81
Kidney cancer 2,414 121 114–130 3% 656 185
Bone and connective tissue cancer 1,890 88 79–99 2% 240 368
Ovarian cancer 1,505 61 55–68 1% 632 97
Multiple myeloma 1,205 58 52–65 1% 488 120
Bladder cancer 1,029 50 44–56 1% 480 104
Cervical cancer 967 39 33–45 1% 213 183
Laryngeal cancer 718 36 31–42 1% 186 192
Non-melanoma skin cancers 639 32 26–37 0.8% 197 163
Gallbladder cancer 544 26 22–30 1% 192 134
Corpus uteri cancer 354 14 43,770 0.3% 183 79
Testicular cancer 237 13 10–16 0.3% 16 793
Eye cancer 126 7 4–9 0.2% 24 275
Thyroid cancer 96 4 3–6 0.1% 54 78
Other malignant neoplasms 3,554 171 158–184 4% 1,131 151
All 87,653 4,200 4,140–
4,258
100% 25,733 163
GDP = Gross Domestic Product; PVLI = Present Value of Lifetime Income; CI = confidence interval
doi:10.1371/journal.pone.0167521.t003
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Discussion
This is the first study to estimate the productivity costs of cancer mortality in Australia. Using
a complete population mortality dataset, we applied a consistent methodology to generate esti-
mates of productivity costs across all major cancer sites and many less prevalent sites. This
enabled highly reliable comparisons of the relative productivity impacts across cancer sites as
Fig 3. Cancer sites with the highest present value of lifetime income (PVLI) forgone, adults age 25–80 at the time of
death in the year 2003. A) Men. From left to right: Lung cancer, colorectal cancer, brain cancer, melanoma, lymphoma. B)
Women. From left to right: Breast cancer, lung cancer, colorectal cancer, brain cancer, ovarian cancer.
doi:10.1371/journal.pone.0167521.g003
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well as various combinations of age and gender. When projected to 2030, premature deaths
from cancer in 2003 were responsible for a total loss of 88,000 full time working years and $4.2
billion in private income forgone.
Our results indicate that the productivity costs associated with cancer sites are broadly
related to the number of deaths, with lung and colorectal cancers together accounting for 35%
of deaths and 30% of the total PVLI impact. Notable exceptions include cancers where deaths
typically occur in a younger and/or predominately male cohort, which can be explained by the
higher productive capacity of these individuals into the future. Specifically, we estimated large
PVLI losses per death for testicular ($793,000), bone and connective tissue ($368,000) and
brain ($325,000) cancers relative to the average loss of $163,000 per premature cancer death.
This compares to the Australian full time adult average annual ordinary time earnings of
$77,168 in 2015 [26]. Conversely, while prostate cancer was the fourth most common cause of
premature cancer death, it was ranked fourteenth in terms of the total PVLI loss. This can be
explained by the lower proportion of deaths in men of working age, with 75% of all prostate
cancer deaths occurring in men aged 75 and over [27].
The difference in the projected working years lost between men (61,000 years) and women
(27,000 years) was notable, and is consistent with results reported elsewhere [6]. Some of this
difference can be explained by the respective number of deaths, with approximately 50% more
premature cancer deaths recorded in men as opposed to women in 2003 (Table 1). However,
differences in labour force dynamics also contribute to this effect. In 2003, the labour force
participation rate for Australian men was 71.3%, compared with 55.8% in women [28]. While
the APPSIM projections we have applied account for the expected increase in female labour
force participation into the future, they also account for projections that women will continue
to be more likely to work part time [29].
Relative to other causes of death, the burden of cancer mortality is high. Cancer contributes
more to the fatal burden of disease in Australia than any other disease category, accounting for
34% of the total years of life lost [30]. Results from LifeLossMOD indicate that cancer accounts
for 30% of the PVLI loss associated with all-cause premature mortality [31].
A growing body of work estimating cancer-related productivity losses has developed in
recent years, with a particular focus on premature mortality costs. In the US, Ekwueme et al
estimated that the total premature mortality cost for all cancers in 2006 was $US 173.1 billion,
equating to 216,701 USD per death. In Europe, these costs have been most recently estimated
at €75 billion in 2008, equating to an average productivity cost of €219,241 per cancer death
[7]. Significant variation in the cost per death between countries were reported, ranging from
a high of €616,230 in Switzerland to a low of €51,925 in Bulgaria.
While most previous studies have produced estimates of productivity costs for all cancers
or a single or small number of cancer sites, we identified two methodologically comparable
studies detailing productivity costs across a large number of cancer sites. Bradley et al esti-
mated cancer related productivity costs across the 19 most common cancer sites in the US [5],
while Hanly et al estimated costs by site for all cancers across Europe [7]. The distribution of
productivity impacts reported in these studies was largely consistent with our findings, with
some exceptions. While lung cancer deaths were responsible for the highest total productivity
cost across all studies, these costs made up a higher proportion of the total PVLI loss in the US
(27%) and Europe (23%) relative to our estimate for Australia (18%). Deaths from colorectal
and breast cancers were also associated with consistently high PVLI losses across studies, rang-
ing from 8–12% of the total PVLI impact. Australia was the only country where melanoma was
included in the top five most costly causes of death. Brain cancers in Australia were responsible
for a relatively higher PVLI loss than those reported for Europe and the US. When estimating
the cost per death, testicular cancer emerged as the most costly cancer site across all studies.
The Productivity Costs of Cancer Mortality
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While these comparisons suggest a broad level of consistency in the distribution of produc-
tivity costs across cancer sites, it is evident that there are limitations in comparing studies
across countries due to differences in the pattern of cancer deaths. This is further exacerbated
by differences in the methodological approach across studies. As noted by Hanly et al in their
recent review, key areas of difference include the method for valuing production losses, the
inclusion of unpaid labour costs, and explicit adjustment for economic variables such as labour
force participation rates, unemployment rates and wage growth rates [6]. The review con-
cluded that there is a need to derive comprehensive estimates of productivity losses associated
with different cancers, in different settings.
The strength of the microsimulation method we have applied was its capacity to project
outcomes on an individual level. This is a key advance over previous studies, allowing for
enhanced complexity and variability to be introduced into the analysis. For example, while
previous studies have been limited to projecting the productivity costs of mortality based on
assumptions around average wage rates, labour force participation and retirement ages, the
estimates we report are able to account for the socioeconomic factors which influence an indi-
vidual’s income and hours worked. In addition, the model incorporated projected trends in
wage growth, labour force participation and actual retirement age, the latter of which is partic-
ularly important given the majority of premature cancer deaths occur beyond the traditional
retirement age.
The microsimulation approach also allows for the assessment of a broader scope of infor-
mation. Previous studies have calculated a Present Value of Lifetime Earnings (PVLE) estimate
to determine the net productivity loss to society, which is based on salary-related earnings
alone. We present a Present Value of Lost Income (PVLI) estimate which is able to account for
all private income, including profits from business and other investments.
It is important to note that in addition to its mortality impact, cancer is also responsible for
significant morbidity with associated productivity costs including the need for time away from
work for both patients and their carers’. The analysis we have presented estimates the produc-
tivity related costs of cancer mortality alone, and as such cannot be considered representative
of the full productivity burden of cancer.
The use of the human capital approach has its limitations. By valuing productivity costs as
the steam of lifetime income forgone, a greater weight is given to cancer deaths affecting youn-
ger working age males, as opposed to groups with lower labour force participation rates and
income including women and the elderly. There have also been assertions that the human capi-
tal approach produces results that are either underestimates [32] or overestimates [33] of the
true cost. In the absence of a universally agreed ‘best practice’ approach, we determined that the
human capital approach was the most appropriate for our purposes given it is the most widely
used method in the recent literature [6], therefore enhancing the comparability of our results.
While the truncation of the modelled analysis at 2030 allows for 27 years of future earnings
to be accounted for, it does not allow for each individual to be followed until their counterfac-
tual retirement or death. The net impact of this truncation point is likely to be minor, with less
than 2% of the total premature death cohort aged 65 years or younger in 2030. In addition, the
3% discount rate applied would necessitate that any costs incurred beyond 2030 be discounted
by over 57% of their actual dollar value. Nonetheless, our results may be considered, in this
sense, a conservative estimate of the total productivity costs of cancer mortality.
Conversely, the inability of the analysis to explicitly account for the potential correlations
between cancer death and common exposures or risk factors among individuals may contrib-
ute to an overestimation of the productivity costs. For example, lung cancer deaths occur pri-
marily among smokers, who are also at significantly increased risk of cardiovascular disease
[34]. This correlation may be in part addressed by our inclusion of socioeconomic status, in
The Productivity Costs of Cancer Mortality
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addition to age and sex, as a characteristic upon which mortality records were matched with
those of the general population in APPSIM. However, this is unlikely to capture all of the excess
mortality risk that could be expected from other causes and as such the analysis may overstate
the years of life lost, and in turn the PVLI loss, associated with premature cancer mortality.
Like most developed countries, Australia has an ageing population nearing retirement. The
proportion of people aged 65 and over is expected to more than double over the next few
decades, resulting in slower workforce and economic growth at the very time that burgeoning
demands are placed on the nation’s health and aged care systems. In this context, measures to
raise labour force participation and productivity are increasingly being recognised as a key pol-
icy focus required to sustain economic growth.
It has been demonstrated that a substantial portion of cancer cases and deaths could be pre-
vented by broadly applying effective prevention measures, such as tobacco control, vaccina-
tion, and the use of early detection tests [2]. This paper highlights the significant labour force
impacts associated with premature mortality, and in turn indicates the likely economic gains
that could accrue with effective interventions. For example, a sustained 2% reduction in lung
cancer mortality would lead to long term productivity savings of approximately $15.3M per
annum, compounding to result in savings of $841.5M over ten years. Such information can
assist decision makers in determining the allocation of resources across competing priorities.
This need not be limited to the decisions within a fixed health care budget. For example, an
awareness of these costs has the potential to promote the diversion of additional resources to
the health care sector away from more traditional measures aimed at increasing productivity,
such as labour force or taxation policy.
Premature mortality cost estimates may also be of value in helping set priorities for future
research. For example, recent evidence has found that clinical trial activity for individual can-
cer site interventions in Australia did not align to the relative burden of disease, with four of
the five cancers that result in the greatest burden of disease (lung, colorectal, prostate and pan-
creatic cancers) significantly underrepresented [35]. Similar mismatches in research funding
and activity have been reported in the US, UK and Canada [36–38]. Estimates of the relative
productivity costs of cancer provides an additional measure of the disease burden that may be
used to help inform research funding allocation.
The productivity impacts of premature mortality due to cancer are significant, resulting in
88,000 workings years lost and a cost of $4.2 billion in private income forgone. These results
provide an assessment of the relative economic costs of cancer mortality by age and sex, and
across multiple cancer sites. The magnitude of these impacts demonstrates the extent of the
societal burden of cancer and the potential economic gains that could be achieved through
investment in effective interventions. This information may assist decision makers in allocat-
ing scare resources amongst competing priorities.
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